Dosage And Administration of Mitomycin

 

Mitomycin is a medication for the treatment of cancer, i.e. a medication which prevents or considerably resists the division of active cells by influencing their metabolism in several ways. The therapeutic use of Mitomycin c 40 mg Injection for the treatment of cancer is based on the fact that one way in which malignant cells differ from the normal cells in the body is that the rate of division of cells is enhanced because of the lack of control of their development. Mitomycin is prescribed in cancer therapy for offering relief of symptoms (palliative cancer therapy).

Intravenous application: When administered Mitomycin intravenously it is used in mono chemotherapy, i.e. treatment with only a single active substance, or along with cytostatic chemotherapy, i.e. treatment with multiple active substances. Mitomycin is useful in the case of the following tumours:

●       advanced metastatic stomach cancer (stomach carcinoma)

●       advanced/metastatic breast cancer (breast carcinoma)

●       respiratory tract cancer (non-small cell bronchial carcinoma)

●       advanced pancreas cancer (pancreatic carcinoma).

Intravesical application: Use in the intravesical application (urinary bladder) to prevent relapse in the case of superficial urinary bladder cancer following the ablation of tissue through the urethra (transurethral resection).

 Dosage & Administration

 Mitomycin injection dosage should only be administered by a health specialist experienced in this kind of therapy. This medicinal product is intended to be used for injection or infusion into a blood vessel (intravenous use) or for introduction into the urinary bladder (intravesical instillation) following being dissolved.

The proposed dose by intravenous administration is 10 to 20 mg/m2 of body surface every 6 to 8 weeks, 8 to 12 mg/m2 of body surface every 3 to 4 weeks, or 5 to 10 mg/m2 of body surface every 1 to 6 weeks. A dose greater than 20 mg/m2 offers more toxic manifestations without therapeutic advantages. The full cumulative dosage of mitomycin is 60 mg/m2.

The proposed dose by intravesical administration is 20 to 40 mg of mitomycin instilled weekly for 8 to 12 weeks. An alternative dosage recommendation to prevent recurrent superficial bladder tumours is 4 to 10 mg (0.06 to 0.15 mg per kg of body weight) instilled into the bladder through a urethral catheter 1/3 times weekly. The solution needs to be retained in the bladder for 1 to 2 hours.

Prior to receiving mitomycin as an injection or infusion into a vein a blood test, evaluation of lung, kidney, and liver function is required in order to exclude any diseases, which could worsen while on the therapy with mitomycin.

The needle needs to remain in the vein while the drug is being given. In case the needle becomes loose, or the medicine is going into the tissue outside the vein (you may experience discomfort or pain); inform your health specialist immediately.